Warren Lammert Joins IntelliMedix Board of Advisors Warren Lammert, Chairman and Co-Founder of the Epilepsy Therapy Project, has been appointed to the Board of accelerated drug discovery and personalized medicine company.
ATLANTA, Feb. 27, 2013 /PRNewswire-iReach/ -- IntelliMedix announced that Warren Lammert has been appointed to its Board. Lammert is the Chairman and co-founder of the Epilepsy Therapy Project and Epilepsy.com and is also a board member for FACES (Finding a Cure for Epilepsy and Seizures) at New York University.
"Warren brings an impressive track record accelerating innovation for new therapies in the field of epilepsy. Warren's drive, passion and proven business acumen will be a great contribution to the Intellimedix team. Warren will help us achieve our goal of finding cures for Dravet Syndrome, epilepsy and other neurological disorders. We are fortunate and excited to have him on board," said Daniel Fischer, President and CEO of Intellimedix.
Mr. Lammert is Founder, Principal and Chief Investment Officer of Granite Point Capital and has more than 18 years of investment industry experience. Prior to the formation of Granite Point Capital, he spent 14 years at Janus serving in several investment and senior management roles, including most recently, Portfolio Manager of the Janus Mercury Fund from its inception in 1993 until March 2003.
"I am thrilled to join with Intellimedix in working to build new approaches to drug discovery for Dravet Syndrome and other orphan and human diseases. Jim Jacoby and Daniel Fischer have assembled a team with a remarkable breadth of expertise but what impresses me most is the range of effective collaborative partnerships that the Intellimedix team has built and nurtured around key emerging discovery technologies," said Warren Lammert.
Also sitting on the Board is Jim Jacoby, Chairman of the Board for IntelliMedix and CEO of Jacoby Development.
IntelliMedix was founded in early 2012 with the purpose of developing and applying novel technologies to accelerate the discovery of new therapies for neurological diseases and creating new approaches for personalized medicine. They employ cutting-edge technology that includes gene sequencing, in silico screening, optogenetics, synthetic biology, and high-throughput in vivo and in vitro models. The company's current focus is on developing new treatments for specific types of intractable epilepsy (e.g., Dravet Syndrome) and other neurological disorders. For more information, please visit http://www.intellimedix.com
Joanna Morrison Intellimedix, 770-399-9930, email@example.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com